Get the Stockscreener App
8.05
2.78%
-0.23
After Hours:
8.07
0.02
+0.25%
Diamedica Therapeutics Inc stock is traded at $8.05, with a volume of 203.27K.
It is down -2.78% in the last 24 hours and down -6.72% over the past month.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
See More
Previous Close:
$8.28
Open:
$8.27
24h Volume:
203.27K
Relative Volume:
0.52
Market Cap:
$419.22M
Revenue:
-
Net Income/Loss:
$-19.90M
P/E Ratio:
-15.19
EPS:
-0.53
Net Cash Flow:
$-19.80M
1W Performance:
-3.59%
1M Performance:
-6.72%
6M Performance:
+109.64%
1Y Performance:
+50.75%
1-Day Range:
$7.95
$8.27
1-Week Range:
$7.95
$8.58
52-Week Range:
$3.19
$10.42
Diamedica Therapeutics Inc Stock (DMAC) Company Profile
Name
Diamedica Therapeutics Inc
Sector
Industry
Phone
(763) 496-5454
Address
301 CARLSON PARKWAY, MINNEAPOLIS, MN
Compare DMAC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMAC
Diamedica Therapeutics Inc
|
8.05 | 431.20M | 0 | -19.90M | -19.80M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
773.94 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.25 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.90 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.09 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-30-25 | Initiated | TD Cowen | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Jun-22-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-09-21 | Initiated | Oppenheimer | Outperform |
| Feb-17-21 | Initiated | ROTH Capital | Buy |
| Oct-30-20 | Initiated | Guggenheim | Buy |
| Jul-08-20 | Initiated | Maxim Group | Buy |
| Apr-30-19 | Initiated | Dougherty & Company | Buy |
| Mar-05-19 | Initiated | Lake Street | Buy |
View All
Diamedica Therapeutics Inc Stock (DMAC) Latest News
DiaMedica Therapeutics (DMAC) price target increased by 25.68% to 15.81 - MSN
Can DiaMedica Therapeutics Inc. stock surprise with earnings upsideTrade Analysis Summary & Growth Focused Stock Pick Reports - Улправда
DiaMedica Therapeutics provides DM199 update following FDA meeting - MSN
Why DiaMedica Therapeutics Inc. stock attracts high net worth investorsGold Moves & Low Volatility Stock Suggestions - Улправда
Is DiaMedica Therapeutics Inc. stock in correction or buying zone2025 Market Outlook & Free Low Drawdown Momentum Trade Ideas - Улправда
Aug Big Picture: Why DiaMedica Therapeutics Inc. stock is a value investor pickInsider Selling & Weekly Watchlist for Hot Stocks - Улправда
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
After-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers - Nasdaq
DiaMedica (DMAC) Advances with FDA in Preeclampsia Study Plans - GuruFocus
DiaMedica Says FDA Seeks Additional Study Ahead of Pre-IND Submission for Preeclampsia Treatment - marketscreener.com
DiaMedica to conduct additional study for preeclampsia treatment - Investing.com
DiaMedica to conduct additional study for preeclampsia treatment By Investing.com - Investing.com Canada
Diamedica Therapeutics provides DM199 preeclampsia program update - marketscreener.com
DiaMedica Advances DM199 Preeclampsia Program After FDA Pre-IND Meeting - TipRanks
DiaMedica Therapeutics Inc Provides DM199 Preeclampsia Program Update - TradingView — Track All Markets
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA - The AI Journal
[8-K] DiaMedica Therapeutics Inc. Reports Material Event | DMAC SEC FilingForm 8-K - Stock Titan
A US$59m Drop in the Market Cap of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Is Not What Insiders Like to See After Purchasing Shares Recently - 富途牛牛
DiaMedica Therapeutics Earnings Notes - Trefis
DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 7.4%Here's Why - MarketBeat
DiaMedica Therapeutics Inc (DMAC) Stock News & Articles - 24/7 Wall St.
Top investors say DiaMedica Therapeutics Inc (DMAC) ticks everything they need - setenews.com
DiaMedica Therapeutics (NASDAQ:DMAC) Sets New 1-Year HighTime to Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA) and Diamedica Therapeutics (DMAC) - The Globe and Mail
DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Jan Stahlberg Purchases 182,882 Shares of Stock - Defense World
DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Jan Stahlberg Buys 187,393 Shares of Stock - Defense World
Jan Stahlberg Acquires 208,872 Shares of DiaMedica Therapeutics (NASDAQ:DMAC) Stock - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Acquires $1,234,453.50 in Stock - MarketBeat
Insider Buying: DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Purchases 128,426 Shares of Stock - MarketBeat
DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Jan Stahlberg Purchases 40,253 Shares - MarketBeat
What dividend safety score for DiaMedica Therapeutics Inc. stock2025 Risk Factors & Fast Gain Stock Tips - Newser
What drives DiaMedica Therapeutics Inc stock priceAnalyst Downgrades & Free Lightning Fast Capital Gains - earlytimes.in
We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth - Yahoo Finance
Private Capital's DiaMedica Therapeutics Inc(DMAC) Holding History - GuruFocus
Why DiaMedica Therapeutics Inc. stock is a value investor pickJuly 2025 Drop Watch & Smart Allocation Stock Tips - moha.gov.vn
There is no way DiaMedica Therapeutics Inc (DMAC) can keep these numbers up - setenews.com
Dir Parsons Acquires 12,000 Of DiaMedica Therapeutics Inc [DMAC] - TradingView
[Form 4] DiaMedica Therapeutics Inc. Insider Trading Activity - Stock Titan
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
DiaMedica In Focus After 52-Week High And FDA Meeting Progress - RTTNews
How DiaMedica Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Intraday Action & Verified Swing Trading Watchlists - newser.com
3 Biotech Stocks Wall Street Analysts Predict Will More Than Double - inkl
HC Wainwright Has Bearish Forecast for DMAC FY2025 Earnings - Defense World
Smart tools for monitoring DiaMedica Therapeutics Inc.’s price actionPortfolio Value Summary & Growth Focused Stock Pick Reports - newser.com
Why analysts remain bullish on DiaMedica Therapeutics Inc. stock2025 Top Gainers & Fast Gaining Stock Reports - newser.com
Published on: 2025-11-19 22:42:15 - newser.com
Diamedica Therapeutics Inc Stock (DMAC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):